Millions of individuals worldwide are on permanent or temporary oral anticoagulation treatment with vitamin K antagonists (VKAs). The effectiveness of VKAs has been established by clinical trials for several indications. Among these, the primary or secondary prevention of venous thromboembolism, the prevention of systemic embolism in patients with prosthetic heart valves, or atrial fibrillation are of highest relevance.1 Such travelers are at higher risk for bleeding episodes due to the anticoagulation and for thromboembolic events due to the underlying disease. This article reviews the most important issues to be considered to give adequate advice to travelers on oral anticoagulants.

Principles of Oral Anticoagulation and Therapy Control

  1. Top of page
  2. Principles of Oral Anticoagulation and Therapy Control
  3. Oral Anticoagulation and Travel
  4. INR Values and the Therapeutic Range
  5. Conclusions
  6. Declaration of Interests
  7. References

Vitamin K is an essential cofactor for the production of functional clotting factors II, VII, IX, and X, as well as inhibitors such as protein C, S, and Z.2 If vitamin K is deficient or the effect of vitamin K is pharmaceutically blocked, the above-mentioned clotting factors cannot be activated, and the dependant clotting time is prolonged. The three available VKAs phenprocoumon, warfarin, and acenocoumarol exert their anticoagulant effect by reducing the regeneration of vitamin K from vitamin K epoxide in the vitamin K cycle.3 The main difference between the different VKAs is the different half-life with the 105 to 114 hours for phenprocoumon, 35 to 45 hours for warfarin, and 9 hours for acenocoumarol.

Several exogenous and endogenous factors influencing the metabolism of vitamin K and its antagonists (eg, nutrition, comedication, antibiotics) result in individual response to the treatment.

The International Normalized Ratio and Patient Self-Management

The small therapeutic range of the oral anticoagulant drugs and the potentially life-threatening effects of both underdosing and overdosing necessitate a close control of the actual intensity of anticoagulation using the international normalized ratio (INR).4 A major improvement toward an increased mobility of patients permanently treated with VKAs was the introduction of self-testing and self-dosing of the oral anticoagulation therapy about 20 years ago. Reliable and easy-to-handle point-of-care-devices for the INR determination such as CoaguCheck, INRatio2, or ProTime are available. Several studies have shown that patient self-management (PSM) results in improved adjustment of the anticoagulation therapy compared to the conventional regime with less frequent INR testing and dosage recommendations done by the physician.5,6 Patients performing self-testing but no self-dosing need to keep in contact with their physician or staff of the anticoagulation clinic. Nowadays, these patients can ask for dosage recommendation from nearly everywhere in the world.

Risks of Patients Under Therapy With Oral Anticoagulants

Patients with mechanical heart valve prosthesis who are anticoagulated more intensively with INR targets up to 4.5 show a yearly incidence of severe and even fatal bleeding episodes between 1.2% to 5.6% and 0.2% to 0.9%, respectively.7 For patients who are treated less intensively with an INR target between 2.0 and 3.0, the incidence of severe bleedings is approximately 0.3% per year.7 The risk for a bleeding episode is higher during the first 3 months of therapy with VKAs.8 Therefore, risky travel should be avoided during this period.

Compared to the above rates, the risk for thromboembolic events greatly varies between 0.2 and 8.1% per patient year and the management of the anticoagulation therapy.1,5

Oral Anticoagulation and Travel

  1. Top of page
  2. Principles of Oral Anticoagulation and Therapy Control
  3. Oral Anticoagulation and Travel
  4. INR Values and the Therapeutic Range
  5. Conclusions
  6. Declaration of Interests
  7. References

Overall, there is only rare and no current scientific data about travel habits or travel-associated incidence of bleeding or thromboembolic episodes of patients under oral anticoagulation.9 The travel-associated influences on oral anticoagulation discussed in the following have one major consequence: intensified INR testing during travel to identify relevant changes at an early stage enabling to take adequate counteractive measures.

Drug Interactions

VKAs are prone to drug–drug interactions.10 This is mainly due to the high binding rate to plasma proteins and the metabolism via cytochrome P450 enzymes resulting in potentiation or inhibition of the anticoagulation effect.1 In general, the patient should be advised to control the INR more often after a new drug has been taken.

Antibiotics and Malaria Prophylaxis

Antibiotic drugs may enhance the anticoagulant effect of VKAs via drug–drug interactions and to a lesser extent through killing of the vitamin K–producing gut flora.10,11 The increase in the risk of bleeding depends on the kind of antibiotic administered and varies considerably.10 Of 62 different antibiotics taken in a large retrospective study, 10 were associated with a significantly increased bleeding risk. The relative risk was three to five for doxycycline, amoxicillin, amoxicillin/clavulanic acid, ciprofloxacin, cotrimoxazole, azithromycin, and pheneticillin; nine for tetracycline; and 43 (!) for cefradine and neomycin.

Doxycycline thus may not be the preferred antimalarial drug in patients on oral anticoagulation therapy. Mefloquine enhances the effect of VKAs due to its high plasma protein binding capacity.12 With regard to relevant interactions with VKA, no data are currently available for Malarone. As the binding rate to plasma proteins of one component of the drug, atovaquone, is very high (>99%), interactions with VKAs are likely. However, according to the product information of the manufacturer, no other drugs with a high-binding capacity to plasma proteins have been displaced by atovaquone in vitro, concluding that no relevant drug interactions via this mechanism could be expected. Although the exact mechanism of the interaction between proguanil and VKAs has not been studied, it is known that proguanil can enhance the anticoagulative effect of VKA. Beside the product information, we are aware of only one patient presenting with increased prothrombin ratio, bruising, and severe hematuria while being on proguanil and warfarin.13 Therefore, it seems to be advisable to start with any kind of chemoprophylaxis at least 1 week before departure. The fear of interactions between VKAs and antimalarial drugs should definitely not discourage patients under oral anticoagulation to take an adequate chemoprophylaxis.

Infectious Diseases

Particularly, infections occurring in subtropical or tropical regions may lead to a procoagulant or hypocoagulant status, which is not always easily recognizable. Acute infections are associated with an increase of the activity of some clotting factors, especially fibrinogen and factor VIII. This may increase the thrombophilic risk and weaken the clinical effect of the anticoagulation therapy, although the INR may remain unaltered. In contrast, a diminished appetite during an infectious disease might lead to a reduced vitamin K uptake, thus enhancing the effect of VKAs. Some infectious diseases such as dengue fever may lead to a lowered platelet count increasing the risk of bleeding.14

Diarrhea and Vomiting

“Travelers’ diarrhea” sometimes associated with vomiting may result in a reduced uptake of vitamin K and the VKA resulting in unstable INR. Antibiotic treatment may further increase the problem.

Dengue Hemorrhagic Fever and Other Hemorrhagic Fevers

The risk for hemorrhagic fevers among travelers is low. Yellow fever is rare mainly due to the application of the vaccine.14 Other infectious agents are virtually restricted to rural or forest areas that are visited only by a small number of travellers.14 Dengue fever occurs more commonly particularly among long-term residents and frequent visitors to endemic areas.

Vaccinations in Patients on Treatment With VKAs

Patients receiving anticoagulant therapy have an increased risk for acquiring hepatitis B.15 Considering the very often underlying chronic diseases of patients on therapy with VKA, an optimal protection against infectious diseases is desirable. As stable liver function is an important issue for patients on treatment with VKA, vaccination against infectious liver disease is especially important. However, because of the risk of hematoma after intramuscular injections, these should be given only when clearly indicated in patients on anticoagulation therapy. Formerly, vaccines were all given subcutaneously until it was recognized that adjuvants induced an unacceptable rate of local reactions16 and that the intramuscular route was possibly associated with better immune response.17

Based upon the available product information, Table 1 gives an overview of injectable vaccines licensed and available in Germany and/or in the United States18,19 and shows which vaccines have central approval in the European Union or are approved via mutual recognition in at least two European countries.20,21 The vaccines listed in groups IV and V remain difficult to handle for patients with increased bleeding risk. If available, the use of alternative vaccines listed in groups I to III or orally or even intranasally applicable vaccines are preferred in patients on oral anticoagulation therapy. The determination of quantitative antibody titers to measure the immune response after subcutaneous vaccination is useful for some of the remaining vaccines listed in group IV.

Table 1.  Route of administration of parenteral applicable vaccines for active immunization of adults with relevance for travel medicine
Preventable diseaseName of vaccine (examples)
  • *

    Recommendation to perform caution steps to avoid the risk of hematoma for patients with bleeding tendency.

  • Seroconversion after first injection more slowly, no difference after second injection.

  • Intramuscular vaccination only after balancing the relationship between risk and benefit.

  • §

    As there are no data available on the subcutaneous administration, a toxic reaction or low efficacy cannot be excluded.

  • Warning of increased incidence of local reactions when given subcutaneously.

  • Also approved in other European countries via mutual recognition.21

  • #

    Central approval in the member states of the European Union.20

  • **

    Licensed in the United States.19

Group I: Administered subcutaneously
 Japanese encephalitisJE-Vax**
 Measles, mumps, rubellaM-M-R II**
 Measles, mumps, rubella, varicellaPriorix-Tetra, ProQuad#,**
 Meningococcal meningitis, A CMeningococcal vaccine Mérieux
 Meningococcal meningitis A, C, W135, and YMencevax ACWY, Menomune**
 VaricellaVarilrix, Varivax¶,**
 Yellow feverStamaril, Yf-Vax**
Group II: Administration either intramuscular or (deeply) subcutaneously
 InfluenzaMany, see package insert
 MeaslesMeasles vaccine Mérieux
 Measles, mumps, rubellaMMR Triplovax, M-M-RvaxPro#, Priorix
 Pneumococcal pneumoniaPneumovax 23¶,**
 RubellaRubella vaccine HDC Mérieux
 TetanusTetanus vaccine Mérieux
 Tetanus, diphtheriaTd vaccine Mérieux
 Typhoid feverTyphim Vi*,**
Group III: Administration primarily intramuscular; no impaired immune response in subcutaneous application
 DiphtheriaDiphtheria adsorbat vaccine Behring
 Hepatitis AHAVpur, Vaqta†,¶,**
 Hepatitis A, typhoid feverViatim
 Hepatitis BRecombivax‖,**
 PoliomyelitisIPV Mérieux
 TetanusMany, see package insert
 Tetanus, diphtheriaMany, see package insert
 Tetanus, diphtheria, poliomyelitisRevaxis
 Tick-borne encephalitisEncepur
Group IV: Administration primarily intramuscular; possible impaired immune response in subcutaneous application
 Hepatitis AHavrix 1440**
 Hepatitis A, hepatitis BTwinrix#,**
 Hepatitis A, typhoid feverHepatyrix
 Hepatitis BEngerix-B Erwachsene¶,**, HBVAXPRO#, Fendrix#
Group V: Administration only intramuscular—subcutaneous alternative not mentioned or explicitly excluded
 H5N1Many, see package insert
 InfluenzaMany, see package insert
 Meningococcal meningitis serogroup CMeningitec, Menjugate Kit‡,¶, NeisVac-C§,¶
 Meningococcal meningitis serogroup A, C, W135 and YMenactra**
 RabiesMany, see package insert
 TetanusVarious, see package insert
 Tetanus, diphtheriaVarious, see package insert
 Tetanus, diphtheria, pertussisAdacel**, Boostrix*,¶,**
 Tetanus, diphtheria, pertussis, poliomyelitisBoostrix Polio*
 Tick-borne encephalitisFSME-Immun
 Typhoid feverTypherix*

The need for intramuscular administration, however, remains for the vaccines listed in group V with no alternative. Risk and benefit must be balanced and caution steps should be taken to avoid the risk of hematoma. The use of a fine needle (≤23 gauge) and the application of firm pressure without rubbing to the injection site for at least 2 minutes are advised.15 Published data and anecdotal experience in large travel clinics on influenza and travel immunization in patients on oral anticoagulation (INR between 2 and 4.5) support this conclusion as no local complications were reported.22–25 The safety of administering influenza vaccine intramusculary in patients on oral anticoagulation with an INR up to 4 was demonstrated very recently.26 In this controlled clinical trial comparing the incidence of side effects after subcutaneous or intramuscular administration of influenza vaccine, no major side effect or hemorrhage was observed in any patient. Moreover, the appearance of local adverse reactions was significantly more frequent in the subcutaneous administration group.26 However, these results may not be generalized to other vaccines or to intramuscular injections with a higher volume or with needles of a greater gauge. As the incidence of a bleeding event is generally dependent on the intensity of the oral anticoagulation, the already low risk of bruising may be further minimized when performing the vaccination at a point in time when the INR of the patient is at the lower limit of the individual target range. The vast majority of patients on oral anticoagulation therapy have INR target ranges of 2.0 to 3.0 or 2.5 to 3.5. The indicated intramuscular vaccination should be performed exceptionally at INR values of approximately 2.0 or 2.5, respectively. Due to lack of scientific data, it is not possible to define an exact threshold INR value below which an intramuscular vaccination can be performed without increased risk of bruising. For the minority of patients with higher INR target ranges as mentioned above, it is rather difficult to give detailed recommendations. Reducing the INR to almost normal levels in these patients and bridging the anticoagulation with better manageable heparin while performing the necessary intramuscular vaccination may be one alternative approach. Whether this procedure is really necessary, however, remains unclear at present. Even more, as in some of the published data on influenza immunization, patients with INR values up to 4.5 were successfully vaccinated without hematoma forming.

In a prospective study, no bruising was detectable at the injection site, while clinically overt bleeding events, mainly mucocutaneous, were recorded in 11 of 104 patients. As INR remained stable in these patients, the authors hypothesized that these bleeding events might be secondary to transient platelet disorders caused by vaccination.22,27

The individual personal history of bleeding tendency and the comedication of the patient have to be considered. The bleeding risk is further increased in a patient a additionally on platelet inhibitors such as acetylsalicylic acid and/or ADP antagonists.

Finally, data on a possible effect of influenza immunization on the INR probably via a transiently depressing of hepatic cytochrome P450 activity are conflicting.28 Whereas the majority of authors did not find such an association,23,24,29–35 others reported a moderate increase36–38 or a slight decrease39,40 of INR. Thus, more closely monitoring of INR after influenza vaccination does not seem to be necessary.24 No significant association between the receipt of pneumococcal, tetanus, or hepatitis A vaccines and changes in INR was found in the only study investigating the effects of other vaccines on oral anticoagulation so far.29


Changes in diet habits are likely to occur on a journey. Patients may be faced with several exotic aliments with unknown vitamin K content, which could have an impact on the INR. Patients should be advised to be reluctant to try new and exotic food or dietary supplements on a journey. Substances such as “royal jelly,” the nourishment of the queen bee, might appear harmless but may have relevant interactions with VKAs.41 Dietary supplements may contain antibiotics, which might affect uptake of vitamin K. Increased drinking of alcoholic beverages could lead to an elevated INR.1

Travel-Associated Changes in Lifestyle

Change in Daily Activities

Lifestyle changes, such as increased or decreased activity, could influence the hormone balance and may have an impact on oral anticoagulation. Given the increased bleeding risks in patients under anticoagulation therapy, travelers should be advised not to try out new activities with a high risk for injuries.

Climatic Influences

High temperature in subtropical or tropical regions can result in an increased bleeding tendency due to vasodilatation independently from the INR. Some authors found lower INR values during spring and summer compared to autumn and winter.42,43 Several possible causes are discussed, such as seasonal differences in sensitivity to warfarin, a higher consumption of vegetables rich in vitamin K in summer, a higher consumption of alcoholic beverages in autumn, and a higher incidence of febrile infectious diseases in autumn and winter as well as a lower compliance in warfarin intake during the holiday season in summer.

Crossing time zones may also have an impact on the regular intake of VKAs. The VKAs with a long half-life, such as warfarin and especially phenprocoumon, seem to be more advantageous. No adjustment is needed as long as the travelers do not cross more than six times zones. For acenocoumarol with a significantly shorter half-life, the intake in constant intervals is important to avoid INR values outside the target range.

For journeys across more than six times zones and longer stays at the destination, several approaches are possible to adapt the intake of the drug to the new time zone. When traveling to the west (prolongation of the day), an additional quarter or half dose of the VKA should to be taken. Vice versa, when traveling to the east (shortening of the day), the first regular dose of the VKA should be reduced by 25% to 50%. An alternative approach is the stepwise adaptation of the daily time of drug intake to the new time. That means when traveling to the east or to the west, the intake of the VKA should be delayed or brought forward for 2 hours per day until the original daily time of drug intake is reached.

Staying at an altitude above 2,400 m is associated with a 2.7-fold increased risk for INR values falling below the target range.44 The causes (eg, effects of hypoxia to coagulation or drug metabolism) remain unclear.

INR Values and the Therapeutic Range

  1. Top of page
  2. Principles of Oral Anticoagulation and Therapy Control
  3. Oral Anticoagulation and Travel
  4. INR Values and the Therapeutic Range
  5. Conclusions
  6. Declaration of Interests
  7. References

Experienced patients might have developed their own successful strategy to correct elevated or lowered INR values. It is important to keep calm as the absolute daily risk of bleeding even at excessive INR elevation is low.1 In case of INR values outside the therapeutic range, INR testing daily or at least every other day is recommended.

Elevated INR and Bleeding Risk During Travel—What To Do?

Omitting or reducing the daily dose of the VKAs is the first and most important measure. In addition, the dietary vitamin K intake may be increased. However, it is difficult to find familiar food rich in vitamin K content abroad. It is therefore advisable to include some vitamin K preparation in the travel kit. Modified from Ansell and colleagues,1 we developed recommendations for well-trained patients on how to manage elevated INR with or without bleeding symptoms on a journey (Table 2).

Table 2.  Recommendation for managing elevated international normalized ratios (INRs) with or without bleeding while traveling abroad*
INR value and clinical symptomsRecommendation (In general more INR testing, once daily or at least every other day)
  • Modified from Ansell and colleagues.1 These recommendations should serve as an approximate guide for well-trained patients performing PSM. Specific circumstances dependent on the patient or kind of travel may lead to modification of the recommended approach. VKA = vitamin K antagonist.

  • *

    If continuing VKA therapy is indicated after high doses of vitamin K, then LMWH can be given until the effects of vitamin K have been reversed.

INR only minimally (up to 0.5) above the upper limit and no significant bleedingNo dose reduction. Wait and see.
INR <5.0 and no significant bleedingLower dose (5%–20% of weekly dose) or stop medication for oral anticoagulation for at least 1 d.
INR <5.0 and minimal bleedingLower dose (5%–20% of weekly dose) or stop medication for oral anticoagulation for 1 d, additionally 1 mg–2.5 mg vitamin K orally (alternatively eat food with a higher vitamin K content, if available). Should visit a medical center.
INR ≥5.0 but <9.0 and no significant bleedingStop medication for oral anticoagulation for at least 1 d, additionally 1 mg–2.5 mg vitamin K orally (alternatively eat food with high vitamin K content, if available). Should visit a medical center.
INR ≥5.0 but <9.0 and minimal bleedingStop medication for oral anticoagulation for at least 1 d, additionally 2.5 mg–5 mg vitamin K orally. Visit a medical center.
INR ≥9.0 and no significant bleedingHold VKA therapy, additionally 2.5 mg–5 mg vitamin K orally. Visit a medical center.
INR ≥9.0 and minimal bleedingHold VKA therapy, additionally 5 mg–10 mg vitamin K orally. Visit a medical center urgently.
Serious or even life-threatening bleeding at any elevation of INRHold VKA therapy, additionally 10 mg Vitamin K orally, Visit a medical center very urgently (Emergency!).

Taking along specific clotting preparations (eg, preparations of the prothrombin complex) on a journey to exotic countries similar to patients with hemophilia A or B should not be considered for patients on oral anticoagulation. Beside logistic problems (adequate transport and storage conditions), such clotting preparations are only indicated in life-threatening bleedings or before urgent operations.45 Furthermore, the application of prothrombin complex preparation is associated with an increased thromboembolic risk caused by the underlying thrombophilic condition and by the drug itself. Especially for carriers of mechanical heart valve prosthesis, this could have a serious impact.

Lowering of the INR and Thromboembolic Risk During Travel—What To Do?

Increasing the dose of VKAs dependent on the decreased INR value in relation to the individual INR target range is the first step. However, especially for patients with a very high thromboembolic risk46 (Table 3), it should be clarified in advance how long an INR below the individual target could be accepted until additional measures might become necessary. According to data from patients with mechanical heart valve prosthesis, thromboembolic events occur mainly after 6 days or more during an uncontrolled interval.5 Therefore, an INR below the individual target should be corrected within 3 to 6 days. If the INR cannot be corrected within 3 days, an additional anticoagulation with heparin is recommended. Both kinds of heparin, low molecular weight heparin (LMWH) and unfractionated heparin (UFH), can be used in therapeutic dosage in principle.47 LMWH may be more appropriate. The dosage of the LMWH should be indicated to the patient prior to departure.

Table 3.  Patients with a high thromboembolic risk (at least 10% annually without anticoagulation [modified46])
Carriers of mechanical heart valve prosthesis, especially in mitral position
Deep vein thrombosis or pulmonary embolism within the last 4 wk
Arterial embolism within the last 4 wk
Atrial fibrillation with
 severe cardial failure
 thrombus in the left atrium
 past ischemic event
 dense spontaneous echoes

Taking Along the INR Self-Testing Device

The safely packed INR self-testing kit should be accompanied by a multilingual or at least English custom declaration testifying the medical necessity and personal use of this kit and the associated equipment such as test strips and lancing devices. Most of the manufacturers of these devices provide custom declarations for free. A certificate is also needed for the LMWH including syringes and needles. As it can be difficult to get supplies even in industrialized countries, a sufficient amount of testing equipment considering the increased number of tests should be taken along. If traveling by air, it is of importance to inform the patient that all equipment and drugs should be carried in the hand luggage.

As far as the information available from the manufacturer, the x-ray at the airport does not harm the function of the devices. Further details of the available INR self-testing kit are summarized in Table 4. The test cuvettes for the ProTime should be stored at 2°C to 8°C to maintain a long shelf life. Therefore, beside the use of cooling bags for transportation, a reliably working refrigerator at the destination is needed, which might be difficult to find in many developing countries.

Table 4.  The most important travel-related features of the currently available point-of-care-devices for INR determination
Name of the deviceCoaguChek XSINRatio2Protime Advantage
ManufacturerRoche Diagnostics GmbH, Mannheim, GermanyHemosense, San Jose, USAITC, Edison, USA
Size (cm × cm)13.8 × 7.814.6 × 7.122.3 × 11.4
Height (cm)2,84,67,1
Weight without batteries (g)127180750
Temperature for usage (°C)18–3210–3515 - 30
Humidity for usage (%)10–8510–95Not given
Power supplyBatteries 4 × 1.5 V AAABatteries 4 × 1.5 V AANet supply, rechargeable batteries
Test methodElectrochemicalImpedancePhoto-optical
INR range0.8–8.00.7–7.50.8 - 9.9
 Test stripsTest stripsTest cuvettes
Size (cm × cm)6.3 × 18.4 × 2.48.0 × 2.5
Needed sample volume (μL)≥10≥15>27
Storage conditions/shelf lifeRoom temperature/12 moRoom temperature/12 mo2°C–8°C/12 mo Room temperature/30 d


  1. Top of page
  2. Principles of Oral Anticoagulation and Therapy Control
  3. Oral Anticoagulation and Travel
  4. INR Values and the Therapeutic Range
  5. Conclusions
  6. Declaration of Interests
  7. References

Traveling while being on oral anticoagulants is possible! Especially for well-trained and informed patients performing a sufficient PSM with a stable INR, there are primarily no contraindications even for journeys to exotic and risky regions. For the safety of the traveling patient, specific information about his mode of travel and the country of destination is necessary. The physician giving medical advice should mention and check the most important issues (see checklist in Table 5).

Table 5.  Travel risk assessment in persons with oral anticoagulation and how to check it
Risk of underlying disease:
✓Is the patient fit for travel considering the underlying disease?
✓Is the journey unavoidable at present? (especially for patients under temporary anticoagulation)
 Self-management of the patient:
✓Does the patient perform a sufficient PSM? If yes, when did he start with it?
✓Is the anticoagulation stable in the targeted INR range?
✓In case of instable INR: May a change to anticoagulation with LMWH be reasonable? How can the control of the platelet  count be managed?
✓Can the patient manage problems with the INR-self-testing device?
  Risk of complications:
✓Does the patient know what to do in case of INR-variations? Intake of vitamin K? Administration of heparin?
✓What to do in case of diarrhea and/or vomitus? Or other infectious diseases? (N.B.: Therapy with antibiotics?)
✓Any new activities planed during the journey? Risk of injury? Alcoholic beverages?
✓Is the patient well instructed on what to do in case of bleeding or clinical signs of thromboembolism?
  Risk of destination:
✓What about the climatic risks?
✓Will the patient be traveling through different time zones?
✓Does the patient know about the alimentation risks during travel?
  Infectious diseases and malaria
✓How is the infectious risk?
✓What kind of vaccinations are needed?
✓Which malaria prophylaxis is appropriate? (N.B: drug interaction)
  Dengue and Hemorrhagic Fevers
  Medical facilities:
✓What is the quality of medicine at the travel destination?
✓Are there any reliable medical centers that the patient could contact if necessary?
✓Multilingual or at least English customs declaration/certification for INR-self-testing device, equipment and medication?
✓Anticoagulation pass and, for carriers of mechanical heart valves, a leaflet with information to prevent endocarditis?
✓Information about the current health status of the patient (latest ECG, echocardiography)
✓Is the INR-self-testing device including test materials and drugs well-packed as hand luggage?
✓Are test strips or cuvettes in sufficient amount?
✓If applicable: Is thermo labile medication/equipment adequately stored?
✓Does the patient need to take Vitamin K preparation with him?
✓Does the patient have sufficient health insurance?


  1. Top of page
  2. Principles of Oral Anticoagulation and Therapy Control
  3. Oral Anticoagulation and Travel
  4. INR Values and the Therapeutic Range
  5. Conclusions
  6. Declaration of Interests
  7. References
  • 1
    Ansell J, Hirsh J, Hylek E, et al. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians evidence-based clinical practice guidelines. 8th Ed. Chest 2008; 133:160S198S.
  • 2
    Shearer MJ. Vitamin K. Lancet 1995; 345:229234.
  • 3
    Choonara IA, Malia RG, Haynes BP, et al. The relationship between inhibition of vitamin K1 2,3-epoxide reductase and reduction of clotting factor activity with warfarin. Br J Clin Pharmacol 1988; 25:17.
  • 4
    Cortelazzo S, Finazzi G, Viero P, et al. Thrombotic and hemorrhagic complications in patients with mechanical heart valve prosthesis attending an anticoagulation clinic. Thromb Haemost 1993; 69:316320.
  • 5
    Koertke H, Minami K, Boethig D, et al. INR self-management permits lower anticoagulation levels after mechanical heart valve replacement. Circulation 2003; 108(Suppl II):II75II78.
  • 6
    Watzke HH, Forberg E, Svolba G, et al. A prospective controlled trial comparing weekly self-testing and self-dosing with the standard management of patients on stable oral anticoagulation. Thromb Haemost 2000; 83:661665.
  • 7
    Levine MN, Raskob G, Landefeld S, Kearon C. Hemorrhagic complications of anticoagulant treatment. Chest 2001; 119:108S121S.
  • 8
    Fihn SD, McDonnel M, Martin D, et al. Risk factors for complications of chronic anticoagulation: a multi-centre study. Warfarin Optimized Out-patient Follow-up Study Group. Ann Intern Med 1993; 118:511520.
  • 9
    Thulin LI. International travel amongst patients on chronic anticoagulation therapy. Cor Vasa 1988; 30:292297.
  • 10
    Penning-van Beest FJ, Koerselman J, Herings RM. Risk of major bleeding during concomitant use of antibiotic drugs and coumarin anticoagulants. J Thromb Haemost 2008; 6:284290.
  • 11
    Visser LE, Penning-van Beest FJ, Kasbergen AA, et al. Overanticoagulation associated with combined use of antibacterial drugs and acenocoumarol or phenprocoumon anticoagulants. Thromb Haemost 2002; 88:705710.
  • 12
    Loefler I. Mefloquine anticoagulant interaction. J Travel Med 2003; 10:194195.
  • 13
    Armstrong G, Beg MF, Scahill S. Warfarin potentiated by proguanil. BMJ 1991; 303:789.
  • 14
    World Health Organization. International travel and health 2008. Available at: (Accessed 2008 Sept 21)
  • 15
    Kroger AT, Atkinson WL, Marcuse EK, Pickering LK; Advisory Committee on Immunization Practices (ACIP) Centers for Disease Control and Prevention (CDC). General recommendations on immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2006; 55(RR-15):148.
  • 16
    Cook IF. Evidence based route of administration of vaccines. Hum Vaccin 2008; 4:67–73.
  • 17
    Zuckerman JN. The importance of injecting vaccines into muscle. BMJ 2000; 321:12371238.
  • 18
    Rote Liste Service GmbH, eds. List of available drugs in Germany [ROTE LISTE] Aulendorf: Editio Cantor Verlag, 2008.
  • 19
    U.S. Food and Drug Administration. Center for biologics evaluation and research. Vaccines licensed for immunization and distribution in the US. Available at: (Accessed 2008 June 30)
  • 20
    European Medicines Agency. European Public Assessment Report for authorised medicinal products for human use. 2008. Available at: (Accessed 2008 Sept 21)
  • 21
    Head of Medicines Agencies. Mutual recognition information product index. 2008. Available at: (Accessed 2008 Sept 21)
  • 22
    Iorio AM, Camillone B, Basileo M, et al. Influenza vaccination in patients on long-term anticoagulant therapy. Vaccine 2006; 24:66246628.
  • 23
    Rai G, Jumar R, McKinney P. Safety of intramuscular influenza immunization among patients receiving long-term warfarin anticoagulation therapy. Arch Intern Med 1995; 155:15291531.
  • 24
    MacCallum P, Madhani M, Mt-Isa S, Ashby D. Lack of effect of influenza immunisation on anticoagulant control in patients on long-term warfarin. Pharmacoepidemiol Drug Saf 2007; 16:786789.
  • 25
    Delafuente JC, Davis JA, Meuleman JR, Jones RA. Influenza vaccination and warfarin anticoagulation: a comparison of subcutaneous and intramuscular route of administration in elderly men. Pharmacotherapy 1998; 18:631636.
  • 26
    Casajuana J, Iglesias B, Fàbregas M, et al. Safety of intramuscular influenza vaccine in patients receiving oral anticoagulation therapy: a single blinded multi-centre randomized controlled clinical trial. BMC Blood Disord 2008; 8:1.
  • 27
    Schattner A. Consequence or coincidence? The occurrence, pathogenesis and significance of autoimmune manifestations after viral vaccines. Vaccine 2005; 23:38763886.
  • 28
    Kramer P, McClain CJ. Depression of aminopyrine metabolism by influenza vaccination. N Engl J Med 1981; 305:12621264.
  • 29
    Jackson ML, Nelson JC, Chen RT, et al. Vaccines and changes in coagulation parameters in adults on chronic warfarin therapy: a cohort study. Pharmacoepidemiol Drug Saf 2007; 16:790796.
  • 30
    Lipsky BA, Pecoraro RE, Roben NJ, et al. Influenza vaccination and warfarin anticoagulation. Ann Intern Med 1984; 100:835837.
  • 31
    Souto JC, Oliver A, Montserrat I, et al. Lack of effect of influenza vaccine on anticoagulation by acenocoumarol. Ann Pharmacother 1993; 27:365368.
  • 32
    Farrow PR, Nicholson KG. Lack of effect of influenza and pneumococcal vaccines on anticoagulation by warfarin. J Infect 1984; 9:157160.
  • 33
    Arnold WS, Mehta MK, Roberts JS. Influenza vaccine and anticoagulation control in patients receiving warfarin. Br J Clin Pract 1990; 44:136139.
  • 34
    Gomolin IH, Chapron MS, Luhan PA. Lack of effect of influenza vaccine on teophylline levels and warfarin anticoagulation in the elderly. J Am Geriatr Soc 1985; 33:269272.
  • 35
    Palache AM. Influenza vaccines. A reappraisal of their use. Drugs 1997; 54:841856.
  • 36
    Kramer P, Tsuru M, Cook CE, et al. Effect of influenza vaccine on warfarin anticoagulation. Clin Pharmacol Ther 1984; 35:416418.
  • 37
    Paliani U, Filippucci E, Gresele P. Significant potentiation of anticoagulation by flu-vaccine during the season 2001-2002. Haematologica 2003; 88:599600.
  • 38
    Weibert RT, Lorentz SM, Norcorss WA, et al. Effect of influenza vaccine in patients receiving long-term warfarin therapy. Clin Pharm 1986; 5:499503.
  • 39
    Poli D, Chiarugi L, Capanni M, et al. Need of more frequent international normalized ratio monitoring in elderly patients on long-term anticoagulant therapy after influenza vaccination. Blood Coagul Fibrinolysis 2002; 13:297300.
  • 40
    Bussey HI, Saklad JJ. Effect of Influenza vaccine on chronic warfarin therapy. Drug Intell Clin Pharm 1988; 22:198201.
  • 41
    Lee NJ, Fermo JD. Warfarin and royal jelly interaction. Pharmacotherapy 2006; 26:583586.
  • 42
    Mannotti C, Quintavalla R, Pattacini C, Pini M. Seasonal variation of oral anticoagulant effect. Thromb Haemost 1994; 71:802803.
  • 43
    Salobir B, Sabovic M, Peternel P. Intensity of long-term treatment with warfarin is influenced by seasonal variations. Pathophysiol Haemost Thromb 2002; 32:151154.
  • 44
    Van Patot MC, Hill AE, Dingmann C, et al. Risk of impaired coagulation in warfarin patients ascending to altitude (>2400 m). High Alt Med Biol 2006; 7:3946.
  • 45
    German Medical Association. Guidelines for the therapy with blood components and plasma derivates. Cologne: Deutscher Aerzteverlag, 2003.
  • 46
    Bauersachs RM, Schellong S, Haas S, et al. Perioperative bridging of oral anticoagulation therapy. Dtsch Aerzteblatt 2007:104:12371244.
  • 47
    Bates SM, Greer IA, Pabinger I, et al. Venous thromboembolism, thrombophilia, antithrombotic therapy, and pregnancy: American College of Chest Physicians evidence-based clinical practice guidelines. 8th Ed. Chest 2008; 133:844S886S.